Top Markets
#1 Siren Siren +30.60%
#2 OriginTrail OriginTrail +26.61%
#3 Waves Waves +12.47%
#4 Tutorial Tutorial +10.44%
#5 MarsCoin MarsCoin +9.18%
#6 Pons Pons +8.78%
#7 Concordium Concordium +6.10%
#8 PulseChain PulseChain +5.89%
#9 Fabric Protocol Fabric Protocol +5.35%
#10 COTI COTI +5.13%
Coin of the day
Siren Siren
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
RaQualia Pharma Inc. RaQualia Pharma Inc.

RaQualia Pharma Inc.

4579
Classifica tra le azioni #22339
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a... RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Prezzo delle azioni
$3.69
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$90.16M
Variazione (1 giorno)
-3.58%
Variazione (1 anno)
0.33%
Paese
JP
Scambia RaQualia Pharma Inc. (4579)

Categoria

Healthcare
Numero di azioni in circolazione per RaQualia Pharma Inc. (4579)
Numero di azioni in circolazione al August 2026: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di RaQualia Pharma Inc., il numero attuale di azioni in circolazione è 0. Alla fine del August 2026, la società aveva 0 azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di RaQualia Pharma Inc. (4579) dal 2026 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
Non abbastanza dati per le date fornite.
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH